Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read original article ↗
Related Articles
Ringg’s AI agents resolve up to 65% of customer calls with OpenAI
Using GPT-5.6, Ringg powers multilingual agents across voice, chat, WhatsApp, and web for 90% less cost vs. GPT-4.1.